New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the treatment of ADHD. Its clinical and safety profile, however, was found to be distinct from other ADHD medications targeting norepinephrine reuptake. Considering the complexity of neuropsychiatric disorders, understanding the mechanism of action (MoA) is an important differentiating point between viloxazine and other ADHD medications and provides pharmacology-based rationale for physicians prescribing appropriate therapy. METHODS: Viloxazine was evaluated in a series of in vitro binding and functional assays. Its effect on neurotransmitter levels in the brain was evaluated using microdialysis in freely moving rats. RESULTS: receptors, along with predicted high receptor occupancy at clinical doses. In vivo, viloxazine increased extracellular 5-HT levels in the prefrontal cortex (PFC), a brain area implicated in ADHD. Viloxazine also exhibited moderate inhibitory effects on the norepinephrine transporter (NET) in vitro and in vivo, and elicited moderate activity at noradrenergic and dopaminergic systems. CONCLUSION: Viloxazine's ability to increase 5-HT levels in the PFC and its agonistic and antagonistic effects on certain 5-HT receptor subtypes, which were previously shown to suppress hyperlocomotion in animals, indicate that 5-HT modulating activity of viloxazine is an important (if not the predominant) component of its MoA, complemented by moderate NET inhibition. Supported by clinical data, these findings suggest the updated psychopharmacological profile of viloxazine can be best explained by its action as a serotonin norepinephrine modulating agent (SNMA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Effects of viloxazine on uptake and cellular functional activity in vitro. (A) Dose-dependent inhibition of NET-mediated [3H]-NE uptake (n = 3) measured in rat hypothalamic synaptosomes and [3H]-5-HT uptake (n = 3) measured in HEK293 cells expressing hSERT. (B) Viloxazine activated the response of 5-HT2C (agonist) in a CHO cell-based IP1 HTRF® assay (n = 2). (C) Viloxazine antagonized the activity of 5-HT2B after stimulation with 5-HT in a CHO cell-based IP1 HTRF® assay (n = 2). Data presented as mean ± SEM.](https://figures.cochat.ai/paper-figures/57c3863e5394475e93151e8f7fcfc621/lt-p-gt-new-insights-into-the-mechanism-of-action-of-viloxazine-serotonin-and-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Atomoxetine raises synaptic norepinephrine and dopamine concentrations in the prefrontal cortex [87], while viloxazine modulates serotonin and norepinephrine [88].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [88]
In the citing paper
“Viloxazine, a norepinephrine reuptake inhibitor with additional effects on the serotonin system [73]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“These results are likely due to the lack of binding affinity of viloxazine at the DAT (KD >100 μM).(18) In addition, viloxazine does not directly interact with the dopaminergic receptors D1 and D2S.”
BackgroundDopamine and drug addiction: the nucleus accumbens shell connection
Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M. A., Spina, L., Cadoni, C., Acquas, E., Carboni, E., Valentini, V., & Lecca, D. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.032 · Cited by 935
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631 · cited 8×
“This is consistent with the longterm cardiac safety profile of viloxazine during its use as an antidepressant in Europe.2,12,62-64 A recently completed randomized clinical trial evaluating the efficacy and safety of extended release viloxazine in the treatment of ADHD, also demonstrated very low rates of cardiovascula…”
ResultInfluentialAmphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
The effects of serotonin in immune cells
Herr, N., Bode, C., & Duerschmied, D. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00048 · Cited by 497
Heel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198224030-00001 · Cited by 384
Fundamentals of Attention-Deficit/Hyperactivity Disorder: Circuits and Pathways
Arnsten, A. F. T. (2006) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 378
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
Wong, E. H. F., Sonders, M. S., Amara, S. G., Tinholt, P. M., Piercey, M. F. P., Hoffmann, W. P., Hyslop, D. K., Franklin, S., Porsolt, R. D., Bonsignori, A., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00291-7 · Cited by 334
Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T., & Perry, K. W. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0986-x · Cited by 334
Locus coeruleus to basolateral amygdala noradrenergic projections promote anxiety-like behavior
McCall, J. G., Siuda, E. R., Bhatti, D. L., Lawson, L. A., McElligott, Z. A., Stuber, G. D., & Bruchas, M. R. (2017) · eLife · doi:10.7554/elife.18247 · Cited by 332
Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2C Receptors
Cryan, J. F., & Lucki, I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39013-5 · Cited by 293
Conio, B., Martino, M., Magioncalda, P., Escelsior, A., Inglese, M., Amore, M., & Northoff, G. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0406-4 · Cited by 254
Koda, K., Ago, Y., Cong, Y., Kita, Y., Takuma, K., & Matsuda, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06750.x · Cited by 222 · cited 2×
“Regarding atomoxetine, it is noteworthy that despite exhibiting a high level of both NET and SERT occupancy (>90% and >85%, respectively),(49) it was not found to functionally increase 5-HT in rat and mouse PFC by microdialysis.(17,38) This finding is possibly due to the low expression levels of SERT in the PFC.”
BackgroundResultADHD and the Prefrontal Cortex
Arnsten, A. F. T. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.018 · Cited by 220 · cited 1×
“The PFC is an established area associated with ADHD pathophysiology, involving the regulation of attention, behavior, and emotions through extensive projections to multiple regions including Acb and Amg, which also play a key role in substance use disorders.(20,21) To better understand the role of viloxazine in modula…”
BackgroundHajós, M., Fleishaker, J. C., Filipiak‐Reisner, J. K., Brown, M. T., & Wong, E. H. F. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00002.x · Cited by 218
Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
Arnsten, A. F. T. (2006) · PubMed · Cited by 208
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.
Wong, D. T., Threlkeld, P. G., Best, K. L., & Bymaster, F. P. (1982) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33153-8 · Cited by 194
Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder
Castellanos, F. X., Elia, J., Kruesi, M. J. P., Gulotta, C. S., Mefford, I. N., Potte, W. Z., Ritchie, G. F., & Rapoport, J. L. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90076-0 · Cited by 181
Krabbe, G., Matyash, V., Pannasch, U., Mamer, L., Boddeke, H. W. G. M., & Kettenmann, H. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.12.002 · Cited by 174
Imaging Functional and Structural Brain Connectomics in Attention-Deficit/Hyperactivity Disorder
Cao, M., Shu, N., Cao, Q., Wang, Y., & He, Y. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8685-x · Cited by 173
Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 166
Self-citationThe role of serotonin in the regulation of patience and impulsivity
Miyazaki, K., Miyazaki, K. W., & Doya, K. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8232-6 · Cited by 162
Oades, R. D., Myint, A.-M., Dauvermann, M. R., Schimmelmann, B. G., & Schwarz, M. J. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-32 · Cited by 144
The neurobiology of attention deficit/hyperactivity disorder
Curatolo, P., Paloscia, C., D'Agati, E., Moavero, R., & Pasini, A. (2009) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2008.06.003 · Cited by 136
Moreau, J., Bös, M., Jenck, F., Martin, J. R., Mortas, P., & Wichmann, J. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00015-6 · Cited by 128
Navailles, S., Moison, D., Cunningham, K. A., & Spampinato, U. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301414 · Cited by 119
Expression of serotonin transporter protein in developing rat brain
Zhou, F. C., Sari, Y., & Zhang, J. K. (2000) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00152-2 · Cited by 111 · cited 4×
“However, a recent study in rats has confirmed that blocking of 5-HT2B receptor located in GABAergic interneurons in dorsal raphe nucleus with a selective 5-HT2B antagonist (RS 127445) can activate 5-HT neuron and enhance 5-HT outflow in medial PFC.40 A similar mechanism is, therefore, postulated for viloxazine – its a…”
BackgroundInfluentialActivation of dorsal raphe serotonin neurons is necessary for waiting for delayed rewards
Miyazaki, K. W., Miyazaki, K., & Doya, K. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0915-12.2012 · Cited by 106
Oades, R. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00440-5 · Cited by 103
Ding, Y., Naganawa, M., Gallezot, J., Nabulsi, N., Lin, S.-F., Ropchan, J. R., Weinzimmer, D. P., McCarthy, T. J., Carson, R. E., Huang, Y. H., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.001 · Cited by 103
Palacios, J. M., Pazos, Á., & Hoyer, D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4545-5 · Cited by 101
Fine-tuning serotonin2c receptor function in the brain: Molecular and functional implications
Berg, K. A., Clarke, W. P., Cunningham, K. A., & Spampinato, U. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.014 · Cited by 99
Davids, E., Zhang, K., Kula, N. S., Tarazi, F. I., & Baldessarini, R. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1097 · Cited by 98
5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
Janssen, W., Schymura, Y., Novoyatleva, T., Kojonazarov, B. K., Boehm, M., Wietelmann, A., Luitel, H., Murmann, K., Krompiec, D., Tretyn, A., et al. (2015) · BioMed Research International · doi:10.1155/2015/438403 · Cited by 94
Sudre, G., Szekely, E., Sharp, W., Kasparek, S., & Shaw, P. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705229114 · Cited by 93 · cited 1×
“Furthermore, functional imaging studies have identified aberrant functional connectivity between sensorimotor, DMN, and cognitive and attentional networks.(75,76) Proper functional interaction between sensorimotor, DMN, and salience networks appears to be regulated by input from the thalamus and striatum, relying on o…”
BackgroundPinder, R. M., Brogden, R. N., Speight, T. M., & Avery, G. S. (1977) · Drugs · doi:10.2165/00003495-197713060-00001 · Cited by 86
He, Y., Fan, M., Sun, Y., & Li, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010012 · Cited by 81
Proposed animal model of attention deficit hyperactivity disorder
Kostrzewa, R. M., Brus, R., Kalbfleisch, J. H., Perry, K. W., & Fuller, R. W. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90013-2 · Cited by 79
Whitney, M. S., Shemery, A. M., Yaw, A. M., Donovan, L. J., Glass, J. D., & Deneris, E. S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-16.2016 · Cited by 77 · cited 8×
“This is consistent with the longterm cardiac safety profile of viloxazine during its use as an antidepressant in Europe.2,12,62-64 A recently completed randomized clinical trial evaluating the efficacy and safety of extended release viloxazine in the treatment of ADHD, also demonstrated very low rates of cardiovascula…”
BackgroundInfluentialThe Impact of Disasters and Their Aftermath on Mental Health: (Commentary)
Ursano, R. J., Cerise, F. P., DeMartino, R., Reissman, D. B., & Shear, M. K. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0102 · Cited by 75
Qureshi, M. N. I., Oh, J., Min, B., Jo, H. J., & Lee, B. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00157 · Cited by 72
Jenck, F., Moreau, J., Berendsen, H. H. G., Boes, M., Broekkamp, C. L. E., Martin, J. R., Wichmann, J., & Delft, A. M. L. V. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00055-2 · Cited by 68
New therapeutic opportunities for 5-HT2 receptor ligands
Maroteaux, L., Ayme‐Dietrich, E., Aubertin-Kirch, G., Banas, S. M., Quentin, E., Lawson, R., & Monassier, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.008 · Cited by 66
Carlier, P. R., LO, M. M. ‐., Lo, P. C.-K., Richelson, E., Tatsumi, M., Reynolds, I. J., & Sharma, T. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00062-6 · Cited by 65
Effects of Norepinephrine Reuptake Inhibition on Postural Tachycardia Syndrome
Green, E. A., Raj, V., Shibao, C. A., Biaggioni, I., Black, B. K., Dupont, W. D., Robertson, D., & Raj, S. R. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000395 · Cited by 64
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719836159 · Cited by 62
Self-citationLeggio, G. M., Cathala, A., Moison, D., Cunningham, K. A., Piazza, P. V., & Spampinato, U. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.10.005 · Cited by 55
Settimo, L., & Taylor, D. M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117742101 · Cited by 52
Del’Guidice, T., Lemay, F., Lemasson, M., Levasseur‐Moreau, J., Manta, S., Etiévant, A., Escoffier, G., Doré, F. Y., Roman, F. S., & Beaulieu, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.313 · Cited by 46
Lippmann, W., & Pugsley, T. A. (1976) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y76-069 · Cited by 45
Brus, R., Nowak, P. G., Szkilnik, R., Mikolajun, U., & Kostrzewa, R. M. (2004) · Neurotoxicity Research · doi:10.1007/bf03033442 · Cited by 41
Papoian, T., Jagadeesh, G., Saulnier, M., Simpson, N. E., Ravindran, A., Yang, B., Laniyonu, A. A., Khan, I. A., & Szarfman, A. (2017) · Toxicologic Pathology · doi:10.1177/0192623317690609 · Cited by 40
Yoo, J. H., Kim, J. I., Kim, B.-N., & Jeong, B. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00164-x · Cited by 38
Cathala, A., Devroye, C., Maître, M., Piazza, P. V., Abrous, D. N., Revest, J., & Spampinato, U. (2014) · Addiction Biology · doi:10.1111/adb.12137 · Cited by 36
Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys
Yanagita, T., Wakasa, Y., & Kiyohara, H. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90430-x · Cited by 30
Chagraoui, A., Whitestone, S., Baassiri, L., Manem, J., Giovanni, G. D., & Deurwaerdère, P. D. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.01.019 · Cited by 30
Spatiotemporal SERT expression in cortical map development
Chen, X., Petit, E., Dobrenis, K., & Sze, J. Y. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.05.010 · Cited by 28
Cathala, A., Devroye, C., Drutel, G., Revest, J., Artigas, F., & Spampinato, U. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.015 · Cited by 27
Nageye, F., & Cortese, S. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1628640 · Cited by 26
Canal, C. E., Morgan, D., Felsing, D. E., Kondabolu, K., Rowland, N. E., Robertson, K. L., Sakhuja, R., & Booth, R. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212373 · Cited by 25
Devroye, C., Cathala, A., Marco, B. D., Caraci, F., Drago, F., Piazza, P. V., & Spampinato, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.012 · Cited by 24
Martin, I. L., Baker, G. B., & Mitchell, P. R. (1978) · Neuropharmacology · doi:10.1016/0028-3908(78)90018-7 · Cited by 22
POTENTIATION OF RESPONSES TO MONOAMINES BY ANTIDEPRESSANTS AFTER DESTRUCTION OF MONOAMINE AFFERENTS
Jones, R. S. G., & Roberts, M. H. T. (1979) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1979.tb07858.x · Cited by 18
Whitestone, S., Deurwaerdère, P. D., Baassiri, L., Manem, J., Anouar, Y., Giovanni, G. D., Bharatiya, R., & Chagraoui, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122925 · Cited by 18
Bharti, S., Rani, N., Bhatia, J., & Arya, D. S. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1083-z · Cited by 16
Viloxazine and neurotransmitter function.
Greenwood, D. T. (1982) · PubMed · Cited by 9
Viloxazine in depressed women: clinical response and cardiovascular effects.
Corona, G. L., Frattini, P., Ml, C., Santagostino, G., Schinelli, S., Zerbi, F., Cairoli, S., Tosca, P., & Savoldi, F. (1987) · PubMed · Cited by 6
Effects of viloxazine on cortical neurone responses to monoamines and acetylcholine [proceedings].
Jones, R. S. G., & Roberts, M. H. T. (1977) · PubMed · Cited by 3
114 An Assessment of QTc Effects With SPN-812 (Extended-Release Viloxazine) in Healthy Adults
Nasser, A. F., Faison, S. L., Liranso, T., Adewole, T., D, M. F. M., Kleiman, R., & Schwabe, S. (2020) · CNS Spectrums · doi:10.1017/s1092852920000322 · Cited by 3
Self-citationJones, R. S. G., & Roberts, M. H. T. (1978) · PubMed · Cited by 2
Research works printed but not linked: 6
- Foye WO. Pharmacodynamic agents In: Foye’s Principles of Medicinal Chemistry. Lemke TL, Williams DA, Roche VF, and Zito SW, eds. UK: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013: 610.
- Greenwood DT. International vivalan symposium; Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975; 3.
- Li D, Kerns EH, edited by. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs; 2015. ISBN 978-1-118-78835-6 (hardback).
- Paxinos G. The Rat Brain in Stereotaxic Coordinates. 6th ed. Academic Press; 2007.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Drug Misuse Research Division, Health Research Board. Literature Review on the Relation Between Drug Use, Impaired Driving and Traffic Accidents (CT.97.EP.14). Lisbon: Portugal; 1999.
- Brody T. FDA’s Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions. Academic Press; 2018: 441– 511.
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Annual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
“The main action of viloxazine is to increase the brain norepinephrine concentrations, but it is also considered to facilitate the neurotransmission of serotonin, and, to a lesser extent, dopamine (Yu et al., 2020; Findling et al., 2021).”
BackgroundAssociation between ADHD and vision problems. A systematic review and meta-analysis
Bellato, A., Perna, J., Ganapathy, P. S., Solmi, M., Zampieri, A., Cortese, S., & Faraone, S. V. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01699-0 · Cited by 87
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
“A recent study found viloxazine to demonstrate weak competitive inhibition (< 25%) at histamine receptors H1 and H2 and muscarinic receptors M1–4, and notably low affinity towards monoamine oxidase A [15].”
BackgroundSelf-citation
Metadata
- Authors
- Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V.
- Affiliations
- Supernus Pharmaceuticals (United States) (US)
- University of South Carolina (US)
- Venue
- Journal of Experimental Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2020-08
- Volume
- Volume 12
- Pages
- 285-300
- ISSN
- 1179-1454 (ISSN-L)
- PMC
- PMC7473988
- OpenAlex
- W3080466884
- Cited by
- 96
- References
- 76
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 16 · 2023: 15 · 2022: 22 · 2021: 20 · 2020: 4
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Experimental Pharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Supernus Pharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- viloxazine, mechanism of action, serotonin transporter, norepinephrine transporter, serotonin receptor antagonism, attention deficit hyperactivity disorder, prefrontal cortex, extracellular serotonin, noradrenergic system, dopaminergic system, norepinephrine reuptake inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.